Janux Therapeutics advances prostate cancer treatment as stock soars
Janux Therapeutics made headlines with an extraordinary 54% surge in after-hours trading on Monday, bringing its stock price to $61.79. This sharp rise followed the ... Read More
Game-changer for prostate cancer: Veracyte’s test predicts who will benefit from chemo
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, has announced compelling new data from the phase 3 STAMPEDE clinical trial demonstrating that its Decipher ... Read More